Karyopharm Therapeutics | KPTI - Операционный доход





Операционный доход Изменить Дата
AbbVie USD 4.73B 1.08B 2026-03
Abbott USD 1.85B 399M 2026-03
Amgen USD 3.83B 130M 2026-03
AstraZeneca USD 7.11B 4.14B 2026-03
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Enanta Pharmaceuticals USD -23.54M 98.15M 2024-12
GlaxoSmithKline GBP 2.29B 856M 2026-03
Incyte USD 324.17M 59.7M 2026-03
J&J USD 6.62B 1.03B 2026-03
Karyopharm Therapeutics USD -17.84M 13.44M 2025-12
MacroGenics USD -12.1M 30.74M 2025-12
Merck USD -1.88B 8.12B 2026-03
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Novartis USD 4.24B 171M 2026-03
Novartis USD 4.06B 521M 2025-12
Pfizer USD 4.99B 340M 2026-03
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Roche Holding CHF 9.56B 3.8B 2025-12
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Takeda JPY -13.62B 182.44B 2026-03
Tectonic Therapeutic USD -21.52M 374K 2025-12
TG Therapeutics USD 34.8M 15.7M 2026-03
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
Xencor USD -77.86M 24.23M 2026-03